Rejoinder to Comments on “Non-Proportional Hazards – An Evaluation of the MaxCombo Test in Cancer Clinical Trials”

References

• Bartlett, J. W., Morris, T. P., Stensrud, M. J., Daniel, R. M., Vansteelandt, S. K., and Burman, C. F. (2020), “The Hazards of Period Specific and Weighted Hazard Ratios,” Statistics in Biopharmaceutical Research, 12, 518–519. DOI: 10.1080/19466315.2020.1755722.
   PubMed Web of Science ®Google Scholar
• Chen, T. T. (2015), “Milestone Survival: A Potential Intermediate Endpoint for Immune Checkpoint Inhibitors,” Journal of the National Cancer Institute, 107, djv156. DOI: 10.1093/jnci/djv156.
   PubMedGoogle Scholar
• Duke-Margolis Workshop. (2018), “Public Workshop: Oncology Clinical Trials in the Presence of Non-Proportional Hazards.” Available at https://healthpolicy.duke.edu/events/public-workshop-oncology-clinical-trials-presence-non-proportional-hazards
   Google Scholar
• FDA Adaptive Design Guidance. (2019), FDA Guidance for Industry. Adaptive Design Clinical Trials for Drugs and Biologics, Silver Spring, MD: U.S. Food and Drug Administration.
   Google Scholar
• FDA Enrichment Strategies for Clinical Trials Guidance. (2019), “Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological Products.”
   Google Scholar
• Freidlin, B., and Korn, E. L. (2019), “Methods for Accommodating Nonproportional Hazards in Clinical Trials: Ready for the Primary Analysis?” Journal of Clinical Oncology: official Journal of the American Society of Clinical Oncology, 37, 3455–3459. DOI: 10.1200/jco.19.01681.
   PubMed Web of Science ®Google Scholar
• Grambsch, P. M., and Therneau, T. M. (1994), “Proportional Hazards Tests and Diagnostics Based on Weighted Residuals,” Biometrika, 81, 515–526. DOI: 10.1093/biomet/81.3.515.
   Web of Science ®Google Scholar
• ICH E9 (R1). (2019), “Addendum on Estimands and Sensitivity Analysis in Clinical Trials - To the Guideline on Statistical Principles for Clinical Trials.”
   Google Scholar
• Li, J., Liu, Q., Yang, H., and Fu, J. (2019), “Reply to Z. McCaw and L-J. Wei,” Journal of Clinical Oncology, 37, 1034. DOI: 10.1200/jco.18.01829.
   PubMedGoogle Scholar
• Lin, R. S., Lin, J., Roychoudhury, S., Anderson, K. M., Hu, T., Huang, B., Leon, L. F., Liao, J. J. Z., Liu, R., Luo, X., Mukhopadhyay, P., Qin, R., Tatsuoka, K., Wang, X., Wang, Y., Zhu, J., Chen, T.-T., and Iacona, R. (2020a), “Alternative Analysis Methods for Time to Event Endpoints Under Nonproportional Hazards: A Comparative Analysis,” Statistics in Biopharmaceutical Research, 12, 187–198. DOI: 10.1080/19466315.2019.1697738.
   Web of Science ®Google Scholar
• Lin, R. S., Lin, J., Roychoudhury, S., Anderson, K. M., Hu, T., Huang, B., Leon, L. F., Liao, J. J. Z., Liu, R., Luo, X., Mukhopadhyay, P., Qin, R., Tatsuoka, K., Wang, X., Wang, Y., Zhu, J., Chen, T.-T., and Iacona, R. (2020b), “Rejoinder to Letter to the Editor “The Hazards of Period Specific and Weighted Hazard Ratios,” Statistics in Biopharmaceutical Research, 12, 520–521. DOI: 10.1080/19466315.2020.1825522.
   PubMed Web of Science ®Google Scholar
• Lin, R. S., Mukhopadhyay, P., Roychoudhury, S., et al. (2023), “Comment on ‘Non-Proportional Hazards – An Evaluation of the MaxCombo Test in Cancer Clinical Trials’ by the Cross-Pharma Non-Proportional Hazards Working Group,” Statistics in Biopharmaceutical Research, 15. DOI: 10.1080/19466315.2022.2103180.
   Web of Science ®Google Scholar
• Luo, X., Mao, X., Chen, X., Qiu, J., Bai, S., and Quan, H. (2019), “Design and Monitoring of Survival Trials in Complex Scenarios,” Statistics in Medicine, 38, 192–209. DOI: 10.1002/sim.7975.
   PubMed Web of Science ®Google Scholar
• Magirr, D., and Burman, C.-F. (2019), “Modestly Weighted Logrank Tests,” Statistics in Medicine, 38, 3782–3790. DOI: 10.1002/sim.8186.
   PubMed Web of Science ®Google Scholar
• Magirr, D., and Burman, C.-F. (2021), “The Strong Null Hypothesis and the MaxCombo Test: Comment on “Robust Design and Analysis of Clinical Trials with Nonproportional Hazards: A Straw Man Guidance form a Cross-Pharma Working Group,” Statistics in Biopharmaceutical Research, 1–2. DOI: 10.1080/19466315.2021.1917451.
   Web of Science ®Google Scholar
• Posch, M., Ristl, R., and König, F. (2022), “Testing and Interpreting the “Right” Hypothesis—Comment on “Non-proportional Hazards—An Evaluation of the MaxCombo Test in Cancer Clinical Trials,” Statistics in Biopharmaceutical Research, 1–2. DOI: 10.1080/19466315.2022.2090431.
   Web of Science ®Google Scholar
• Prior, T. J. (2020), “Group Sequential Monitoring Based on the Maximum of Weighted Log-Rank SStatistics with the Fleming-Harrington Class of Weights in Oncology Clinical Trials,” Statistical Methods in Medical Research, 29, 3525–3532. DOI: 10.1177/0962280220931560.
   PubMed Web of Science ®Google Scholar
• Ristl, R., Ballarini, N. M., Götte, H., Schüler, A., Posch, M., and König, F. (2021), “Delayed Treatment Effects, Treatment Switching and Heterogeneous Patient Populations: How to Design and Analyze RCTs in Oncology,” Pharmaceutical Statistics, 20, 129–145. DOI: 10.1002/pst.2062.
   PubMed Web of Science ®Google Scholar
• Roychoudhury, S., Anderson, K. M., Ye, J., and Mukhopadhyay, P. (2021), “Robust Design and Analysis of Clinical Trials With Nonproportional Hazards: A Straw Man Guidance From a Cross-Pharma Working Group,” Statistics in Biopharmaceutical Research, 1–15. DOI: 10.1080/19466315.2021.1874507.
   Web of Science ®Google Scholar
• Shen, Y.-L., Wang, X., Mushti, S., Mulkey, F., Zhou, J., Gao, X., Zhang, L., Gwise, T., Tang, S., Theoret, M., Pazdur, R., and Sridhara, R. (2021), “Non-Proportional Hazards – An Evaluation of the MaxCombo Test in Cancer Clinical Trials,” Statistics in Biopharmaceutical Research, 1–10. DOI: 10.1080/19466315.2021.2008485.
   Web of Science ®Google Scholar